Abstract
RNA interference (RNAi) is a mechanism in which double-stranded (ds) RNA acts as a guide to sequence-specifically suppress gene expression. To achieve targeted knock-downs of gene function in mammalian cells, in vitro synthesised small interfering RNAs (siRNAs) can be introduced transiently into cells or, for more stable suppression by RNAi, various vector strategies can be employed to achieve prolonged in vivo synthesis of targeting RNA sequences. RNAi, beyond being a powerful experimental tool, has been widely promoted as a future gene-targeted therapeutic strategy of exquisite specificity. In the context of cancer, in which mutation, over-expression and de-novo acquisition of tumour-promoting genes are of central importance to the pathology, multiple molecular targets have been proposed for RNAi-based therapies. In this review, we will summarise what is known about the biology of RNAi in mammalian cells, outline the various expression and delivery strategies that have been developed, and discuss the features of possible therapeutic gene targets. We will also highlight the present technical limitations of RNAi that will need to be addressed if it is to be developed therapeutically, including the important issues of effective delivery and the potential for development of tumour resistance.
Keywords: cancer, rnai, rna interference, therapy, tumor
Current Cancer Therapy Reviews
Title: RNA Interference: A New Targeted Tumour Therapy?
Volume: 1 Issue: 1
Author(s): Jane M.E. Withey and Mark R. Crompton
Affiliation:
Keywords: cancer, rnai, rna interference, therapy, tumor
Abstract: RNA interference (RNAi) is a mechanism in which double-stranded (ds) RNA acts as a guide to sequence-specifically suppress gene expression. To achieve targeted knock-downs of gene function in mammalian cells, in vitro synthesised small interfering RNAs (siRNAs) can be introduced transiently into cells or, for more stable suppression by RNAi, various vector strategies can be employed to achieve prolonged in vivo synthesis of targeting RNA sequences. RNAi, beyond being a powerful experimental tool, has been widely promoted as a future gene-targeted therapeutic strategy of exquisite specificity. In the context of cancer, in which mutation, over-expression and de-novo acquisition of tumour-promoting genes are of central importance to the pathology, multiple molecular targets have been proposed for RNAi-based therapies. In this review, we will summarise what is known about the biology of RNAi in mammalian cells, outline the various expression and delivery strategies that have been developed, and discuss the features of possible therapeutic gene targets. We will also highlight the present technical limitations of RNAi that will need to be addressed if it is to be developed therapeutically, including the important issues of effective delivery and the potential for development of tumour resistance.
Export Options
About this article
Cite this article as:
Withey M.E. Jane and Crompton R. Mark, RNA Interference: A New Targeted Tumour Therapy?, Current Cancer Therapy Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573394052952447
DOI https://dx.doi.org/10.2174/1573394052952447 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design What Does Systems Biology Mean for Drug Development?
Current Medicinal Chemistry in vitro Anti-leukaemia Activity of Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs)
Recent Patents on Anti-Cancer Drug Discovery MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Intracellular ROS Generation Mediates Maleimide-induced Cytotoxicity in Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry The Tachykinergic System as Avenues for Drug Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)
Current Cancer Drug Targets Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer
Current Cancer Drug Targets Protein Interaction Domains: Structural Features and Drug Discovery Applications (Part 2)
Current Medicinal Chemistry Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
Current Pharmaceutical Design Metabolomics: A Revolution for Novel Cancer Marker Identification
Combinatorial Chemistry & High Throughput Screening N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Nelarabine- A New Purine Analog in the Treatment of Hematologic Malignancies
Reviews on Recent Clinical Trials Major Challenges for Gene Therapy of Thalassemia and Sickle Cell Disease
Current Gene Therapy Innate Immunity and the Heart
Current Pharmaceutical Design The Role of IRF1 and IRF2 Transcription Factors in Leukaemogenesis
Current Gene Therapy Molecular Targeting of Protein Kinases to Optimize Selectivity and Resistance Profiles of Kinase Inhibitors
Current Topics in Medicinal Chemistry Approaches to Target Profiling of Natural Products
Current Medicinal Chemistry